ArticlePharmacoEconomics - open2019

Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England.

D Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.